Aushon Biosystems and Peking University Cancer Hospital Collaboration to Focus on Predictive Diagnostic Biomarkers for Liver Metastases of Colorectal Cancer
Published: Feb 08, 2011
BILLERICA, Mass.--(BUSINESS WIRE)--Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services announced that it has signed a letter of intent to enter into a diagnostic development collaboration with Peking University Cancer Hospital (“PUCH”), Beijing, China. The primary goal for the collaboration is to develop predictive diagnostic markers for liver metastases of colorectal cancer utilizing Aushon’s proprietary suite of protein biomarker detection technologies, and stratification biomarkers for radio-chemotherapy patients. As part of this collaboration, PUCH and Aushon will further negotiate an agreement to grant Aushon exclusive rights In North America and Europe to certain intellectual property generated from the collaboration for diagnostic applications.